所有图片(1)
别名:
盐酸安非他酮吗啉代杂质, GW 353162, SS-羟基安非他酮盐酸盐, 盐酸拉达法辛, （+）-（2S，3S）-2-（3-氯苯基）-3,5,5-三甲基-2-吗啉代盐酸盐, （2S，3S）-2-（3-氯苯基）-3,5,5-三甲基-2-吗啉代盐酸盐
经验公式（希尔记法）:
C13H18ClNO2 · HCl
推荐产品
质量水平
检测方案
≥98% (HPLC)
形式
powder
储存条件
desiccated
颜色
white to tan
溶解性
DMSO: ≥12 mg/mL
储存温度
−20°C
SMILES字符串
Cl.C[C@@H]1NC(C)(C)CO[C@@]1(O)c2cccc(Cl)c2
InChI
1S/C13H18ClNO2.ClH/c1-9-13(16,17-8-12(2,3)15-9)10-5-4-6-11(14)7-10;/h4-7,9,15-16H,8H2,1-3H3;1H/t9-,13+;/m0./s1
InChI key
ORXTVTDGPVINDN-BTJVGWIPSA-N
一般描述
(2S,3S)-羟基安非他酮是安非他酮的主要代谢产物。
生化/生理作用
（2S，3S）-羟基安非他酮是多巴胺转运蛋白（DAT）和去甲肾上腺素转运蛋白（NET）转运蛋白抑制剂和烟碱型乙酰胆碱受体（nAChR）家族调节剂。 据报道，羟基安非他酮有助于抗抑郁和戒烟。(2S,3S)和(2R,3R)代谢产物均可逆转尼古丁依赖性小鼠的情感和躯体戒断症状，但(2S,3S)-羟基安非他酮更有效。(2S,3S)-羟基安非他酮可显著降低小鼠的尼古丁奖赏效应。
特点和优势
该化合物收录于 受体分类和信号转导手册的《生物胺转运体 》页面。想要浏览手册的其他页面， 请单击此处。
警示用语：
Warning
危险声明
危险分类
Eye Irrit. 2
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Yating Deng et al.
Drug metabolism and pharmacokinetics, 28(4), 339-344 (2013-02-20)
Gentiopicroside (GE), a naturally occurring iridoid glycoside, has been developed into a Novel Traditional Chinese Drug named gentiopicroside injection, and it was approved for the treatment of acute jaundice and chronic active hepatitis by SFDA. However, the inhibitory and inducible
E Malcolm et al.
Psychopharmacology, 232(15), 2763-2771 (2015-03-13)
Preclinical studies with bupropion in rodent models of nicotine dependence have generated equivocal findings with regard to translating the clinical efficacy of the antidepressant as a smoking cessation agent. Given that rats are poor metabolizers of bupropion, the present experiments
Matthew L Banks et al.
Behavioural pharmacology, 27(2-3 Spec Issue), 196-203 (2016-02-18)
The dopamine transporter (DAT) inhibitor and nicotinic acetylcholine (nACh) receptor antagonist bupropion is being investigated as a candidate 'agonist' medication for methamphetamine addiction. In addition to its complex pharmacology, bupropion also has two distinct pharmacologically active metabolites. However, the mechanism
Rajesh Chavan et al.
Xenobiotica; the fate of foreign compounds in biological systems, 51(3), 251-261 (2020-10-21)
Nafithromycin is a next generation lactone ketolide antibiotic slated to enter phase III clinical development in India for the treatment of CABP as a shorter 800 mg-OD X3 day therapeutic regimen. Nafithromycin exhibits potent activity against MDR Streptococcus pneumoniae including erythromycin and
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门